Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
Abstract Diffuse large B-cell lymphoma (DLBCL) may present initially in bone marrow, liver and spleen without any lymphadenopathy (referred to as BLS-type DLBCL), which is aggressive and frequently associated with hemophagocytic syndrome. Its tumorigenesis and molecular mechanisms warrant clarificat...
Guardado en:
Autores principales: | Kung-Chao Chang, Ruo-Yu Chen, Yu-Chu Wang, Liang-Yi Hung, L. Jeffrey Medeiros, Ya-Ping Chen, Tsai-Yun Chen, Jui-Chu Yang, Po-Min Chiang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68dd808b9c9d4c91a9092e920931f2c1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.
por: Kung-Chao Chang, et al.
Publicado: (2013) -
Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021) -
STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas
por: Yi-Ru Pan, et al.
Publicado: (2018) -
Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
por: Kirsten Thobe, et al.
Publicado: (2021) -
TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021)